Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiprubart (KPL-404) in moderate to severe rheumatoid arthritis
NCT05198310Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of Abiprubart in rheumatoid arthritis (RA), sponsored by Kiniksa Pharmaceuticals. Started Dec 2021; status: completed.
02
Drugs
Abiprubart
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05198310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198310.